source
- UniQure to release four-year Huntington’s gene therapy results by SeptemberUniQure, a biotech firm, will report four-year data from its Huntington’s disease gene therapy trial before the end of September. The therapy, AMT-130, has already been submitted to regulators in…
- FDA signals openness to innovative approaches for psychedelic drug developmentFDA officials said the agency is open to novel, innovative approaches to the clinical development of psychedelic drugs, citing the worsening mental health crisis in the United States. The agency’s…